Cyclacel Pharmaceuticals (CYCC) Receives Media Sentiment Score of 0.22

News articles about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9255081835457 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

Shares of Cyclacel Pharmaceuticals (NASDAQ CYCC) opened at 2.00 on Monday. Cyclacel Pharmaceuticals has a one year low of $1.56 and a one year high of $10.90. The firm’s 50-day moving average price is $1.78 and its 200-day moving average price is $3.47.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter. On average, equities research analysts expect that Cyclacel Pharmaceuticals will post ($2.25) EPS for the current year.

In other news, major shareholder Eastern Capital Ltd acquired 850,000 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $1,700,000.00. Following the completion of the transaction, the insider now owns 2,167,261 shares of the company’s stock, valued at $4,334,522. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.00% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://ledgergazette.com/2017/10/09/cyclacel-pharmaceuticals-cycc-receives-media-sentiment-score-of-0-22.html.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply